The DuraSite 2 was designed to develop topically delivered ocular drugs with enhanced tissue penetration. The patent will protect the technology’s delivery system and drugs formulated until 2029.
More Articles on Ophthalmology:
Femtosecond Laser Technology May Provide Alternative to Corneal Keratoplasty
Cataract Surgery Improve Vision in Retinitis Pigmentosa Sufferers, Study Says
Atlantic Eye Center in New Jersey Turns 25
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
